Aviva PLC Sells 4,223 Shares of Cencora, Inc. (NYSE:COR)

Aviva PLC lessened its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 1.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 221,080 shares of the company's stock after selling 4,223 shares during the quarter. Aviva PLC owned approximately 0.11% of Cencora worth $49,672,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in COR. JFS Wealth Advisors LLC grew its holdings in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after acquiring an additional 46 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Cencora during the fourth quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC grew its stake in shares of Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after purchasing an additional 69 shares during the last quarter. Kentucky Trust Co purchased a new position in Cencora during the 4th quarter valued at about $33,000. Finally, WASHINGTON TRUST Co raised its position in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on COR. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Wells Fargo & Company lifted their target price on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Finally, Bank of America increased their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $284.20.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the sale, the chairman now directly owns 317,913 shares in the company, valued at approximately $85,680,732.63. This trade represents a 4.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the company's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the transaction, the executive vice president now owns 14,665 shares in the company, valued at approximately $3,934,326.20. This represents a 21.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,675 shares of company stock valued at $8,034,778 in the last quarter. 10.80% of the stock is owned by insiders.

Cencora Stock Up 1.6 %

COR traded up $4.41 during midday trading on Friday, reaching $283.56. The company's stock had a trading volume of 523,899 shares, compared to its average volume of 1,500,078. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $296.65. The stock's 50-day moving average is $259.61 and its 200-day moving average is $244.58. The firm has a market capitalization of $54.99 billion, a price-to-earnings ratio of 40.30, a PEG ratio of 1.31 and a beta of 0.55. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.78%. Cencora's payout ratio is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.